NCT07526493 2026-04-13
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Phase 1 Recruiting
Clinical Trials
12 trialsNCT06371040 2025-09-15
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Recruiting
NCT07154095 2025-09-04
A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese Participants
West China Second University Hospital
Phase 1 Completed
NCT06249438 2025-07-25
CAR-AID
RenJi Hospital
Phase 1 Recruiting
NCT04965987 2025-07-11
Oxaloacetate in Myasthenia Gravis
University of Kansas Medical Center
Phase 1 Withdrawn
NCT06869278 2025-06-11
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Recruiting
NCT06978738 2025-05-18
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Changzhou No.2 People's Hospital
Phase 1 Not yet recruiting
NCT06958939 2025-05-06
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Not yet recruiting
NCT06759948 2025-01-06
KY2024-853
Huashan Hospital
Phase 1 Not yet recruiting
NCT05828225 2023-04-25
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis
Zhejiang University
Phase 1 Recruiting
NCT01828294 2019-04-03
SIMM
St. Louis University
Phase 1 Terminated
NCT00424489 2018-08-31
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Northwestern University
Phase 1 Terminated